Fortrea Holdings Inc. (FTRE)
NASDAQ:FTRE
Want to see FTRE full AI Analyst Report?
FTRE Stock Chart & Stats
$10.38
-$0.82(-4.27%)
At close: 4:00 PM EST
$10.38
-$0.82(-4.27%)
Day’s Range― - ―
52-Week Range$3.97 - $18.67
Previous CloseN/A
Volume188.47K
Average Volume (3M)1.80M
Market Cap
$1.48B
Enterprise Value$1.39B
Total Cash (Recent Filing)$174.60M
Total Debt (Recent Filing)$68.00M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Aug 17, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.97
Shares Outstanding93,500,000
10 Day Avg. Volume2,205,510
30 Day Avg. Volume1,801,545
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.58
P/FCF Ratio17.82
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue0.51
Enterprise Value/Gross Profit3.12
Enterprise Value/Ebitda-1.71
Forecast
1Y Price Target
$15.38Price Target Upside48.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)0.71
Revenue Forecast (FY)$2.59B
Bulls Say, Bears Say
Bulls Say
Customer DemandAnalyst upgrade to Buy highlights rising customer contract activity and more stable budgets at large pharmaceutical customers, indicating strengthening demand for the company's services.
Operational Execution And BookingsManagement's progress on a refreshed strategic plan alongside net bookings above expectations signals improving operational momentum that may support revenue recovery.
Profitability And MarginsNormalizing pass-through costs combined with planned cost reductions are expected to improve margins, supported by adjusted profitability that exceeded expectations.
Bears Say
AI Disruption ConcernsShare price weakness reflects market worries about disruption from artificial intelligence, creating investor uncertainty about future demand patterns.
Growth VisibilityCompany guidance projecting revenue below analyst expectations while profitability guidance is roughly in line creates uncertainty about the sustainability of revenue growth.
Guidance RiskNear-term guidance was lighter than analysts expected, which reduces near-term upside potential and increases valuation risk.
Fortrea Holdings Inc. News
FTRE FAQ
What was Fortrea Holdings Inc.’s price range in the past 12 months?
Fortrea Holdings Inc. lowest stock price was $3.97 and its highest was $18.67 in the past 12 months.
What is Fortrea Holdings Inc.’s market cap?
Fortrea Holdings Inc.’s market cap is $1.48B.
When is Fortrea Holdings Inc.’s upcoming earnings report date?
Fortrea Holdings Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 102 days.
How were Fortrea Holdings Inc.’s earnings last quarter?
Fortrea Holdings Inc. released its earnings results on May 05, 2026. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.061 by $0.099.
Is Fortrea Holdings Inc. overvalued?
According to Wall Street analysts Fortrea Holdings Inc.’s price is currently Undervalued.
Does Fortrea Holdings Inc. pay dividends?
Fortrea Holdings Inc. does not currently pay dividends.
What is Fortrea Holdings Inc.’s EPS estimate?
Fortrea Holdings Inc.’s EPS estimate is 0.18.
How many shares outstanding does Fortrea Holdings Inc. have?
Fortrea Holdings Inc. has 93,500,000 shares outstanding.
What happened to Fortrea Holdings Inc.’s price movement after its last earnings report?
Fortrea Holdings Inc. reported an EPS of $0.16 in its last earnings report, beating expectations of $0.061. Following the earnings report the stock price went up 18.612%.
Which hedge fund is a major shareholder of Fortrea Holdings Inc.?
Currently, no hedge funds are holding shares in FTRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fortrea Holdings Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.38 (48.12% Upside)
$15.38 (48.12% Upside)
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.29%
12-Months-Change
Fundamentals
Return on Equity
-79.12%
Trailing 12-Months
Asset Growth
-14.02%
Trailing 12-Months
Company Description
Fortrea Holdings Inc.
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
FTRE Company Deck
FTRE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced clear operational and commercial progress (book-to-bill >1.1x, adjusted EBITDA growth, large backlog, strong cost savings, FIT launch, China momentum and improved cash flow metrics) against near-term revenue pressure driven by lower pass-throughs and FSP pricing concessions, customer concentration and continued negative (though improved) Q1 cash flow. Management reiterated full-year guidance and a multi-year plan to reach mid-teens adjusted EBITDA margins. Overall, the positive operational, financial and commercial momentum and materially improved profitability and cash metrics outweigh the listed headwinds.View all FTRE earnings summariesFTRE Stock 12 Month Forecast
Average Price Target
$15.38
▲(48.12% Upside)
Technical Analysis
Nektar Therapeutics
―
Fulcrum Therapeutics
―
Compass Therapeutics
―
Erasca
―
Aura Biosciences Inc
―
Ownership Overview
0.39% Insiders
18.70% Mutual Funds
0.99% Other Institutional Investors
45.46% Public Companies and
Individual Investors